Henry Schein (HSIC) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Natera (NTRA) has outperformed Henry Schein (HSIC) over the past year, gaining 18.5% versus a gain of 13.8%. Over five years, NTRA leads with a +188.8% price change compared with +13.4% for HSIC. Natera is the larger company by market cap ($39.64 billion vs $9.23 billion), about 4.3 times the size.
Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSIC | NTRA |
|---|---|---|
| Share price | $83.52 | $273.40 |
| Market cap | $9.23B | $39.64B |
| 1-day change | -1.51% | -5.70% |
| YTD return | +10.51% | +19.34% |
| 1-year return | +13.79% | +18.54% |
| 5-year return | +13.42% | +188.82% |
| P/E ratio (TTM) | 22.88 | — |
| Forward P/E | 13.91 | — |
| EPS (TTM) | $3.65 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.18B | $2.31B |
| Revenue growth (YoY) | +4.03% | +35.90% |
| Net income (latest FY) | $398.00M | $-208.16M |
| Gross margin | 31.14% | — |
| Operating margin | 4.95% | -13.44% |
| Net margin | 3.02% | -9.03% |
| 52-week high | $92.18 | $437.41 |
| 52-week low | $68.70 | $181.00 |
| Distance from 52-week high | -9.39% | -37.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +15.98% | +50.06% |
| Average volume | 1.33M | 1.77M |
| Shares outstanding | 110.54M | 145.00M |
| Employees | 25,000 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Natera is about 4.3 times larger than Henry Schein by market value ($39.64B vs $9.23B).
- Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +4.03%).
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
HSIC vs NTRA FAQ
Which is bigger, Henry Schein or Natera?
Natera (NTRA) is larger, with a market capitalization of $39.64B compared with $9.23B for Henry Schein (HSIC).
Which stock has performed better over the past year, HSIC or NTRA?
NTRA returned +18.54% over the past 12 months, compared with +13.79% for HSIC (price return, excluding dividends). Past performance does not predict future results.
Are Henry Schein and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.